Collagen degradation in I-cells is normal.
There is evidence that lysosomal proteases mediate the intracellular degradation of structurally abnormal collagen. I-Cell disease (Mucolipidosis II) is characterized by marked deficiency of many lysosomal hydrolases, including the collagenolytic enzyme cathepsin B. The experiments reported here tested the hypothesis that degradation of abnormal collagen would be severely impaired in I-cells. Skin fibroblasts from 3 patients with I-cell disease were incubated with and without cis-hydroxyproline, a proline analog that causes structural abnormalities in collagen, and [14C]proline. The amount of [14C]hydroxyproline in a low molecular weight fraction relative to total [14C]hydroxyproline was used as a measure of intracellular collagen degradation. Levels of degradation were significantly higher in I-cells exposed to cis-hydroxyproline than in cells incubated without the analog. Similar data were obtained for normal human fetal lung fibroblasts incubated under the same conditions. Degradation of [125I]-epidermal growth factor was used to assess the functionality of the lysosomal pathway for protein degradation, and it was much lower in I-cells than in normal cells. It can be concluded that a completely functional complement of lysosomal enzymes is not necessary for structurally abnormal collagen to be degraded intracellularly; the data suggest that a nonlysosomal pathway exists.
Bienkowski
R S
RS
Pediatric Research Center, Schneider Children's Hospital of Long Island Jewish Medical Center, New Hyde Park, New York 11042.
Ripley
C R
CR
Gitzelmann
R
R
Steinmann
B
B
D002478:Cells, Cultured; D003094:Collagen / Q000378:metabolism*; D004815:Epidermal Growth Factor / Q000494:pharmacology; D005347:Fibroblasts; D006801:Humans; D006909:Hydroxyproline / Q000494:pharmacology*; D008297:Male; D009081:Mucolipidoses / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D011489:Protein Denaturation
D004815:Epidermal Growth Factor; D003094:Collagen; D006909:Hydroxyproline